BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 9552057)

  • 1. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
    Rose PG; Fusco N; Fluellen L; Rodriguez M
    J Clin Oncol; 1998 Apr; 16(4):1494-7. PubMed ID: 9552057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
    Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
    Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy.
    Eltabbakh GH; Yildirim Z; Adamowicz R
    Am J Clin Oncol; 2004 Feb; 27(1):46-50. PubMed ID: 14758133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma.
    Balbi G; Di Prisco L; Musone R; Menditto A; Cassese E; Balbi C; Cardone A
    Eur J Gynaecol Oncol; 2002; 23(4):347-9. PubMed ID: 12214742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Fusco N
    Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
    Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
    Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
    Dizon DS; Hensley ML; Poynor EA; Sabbatini P; Aghajanian C; Hummer A; Venkatraman E; Spriggs DR
    J Clin Oncol; 2002 Mar; 20(5):1238-47. PubMed ID: 11870166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S
    Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Arimoto T; Nakagawa S; Oda K; Kawana K; Yasugi T; Taketani Y
    Med Oncol; 2012 Jun; 29(2):1253-4. PubMed ID: 21380784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
    Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
    Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.